Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report)’s share price was up 0.8% on Thursday . The stock traded as high as $10.18 and last traded at $10.18. Approximately 600 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 6,060 shares. The stock had previously closed at $10.10.
Telix Pharmaceuticals Price Performance
The firm has a 50-day moving average of $8.65 and a two-hundred day moving average of $7.42.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals
- Using the MarketBeat Dividend Yield Calculator
- Roblox: The Bottom Just Fell Out of the Metaverse
- How to Use the MarketBeat Dividend Calculator
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What is a buyback in stocks? A comprehensive guide for investors
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.